Orphan Drug Development
Orphan drug trials are not just smaller versions of large trials and have specific requirements. We focus on the rare disease patient, and how to make a positive impact on their lives.
Our orphan team is led by PSR Orphan Experts (PSR), Ergomed’s rare disease subsidiary. PSR is one of the few companies exclusively focused in orphan disease drug development and recognised as a leading expert in assisting biotech and pharma companies in the rare disease niche. Through our Site Management model and Study Physician Team Support, we find the hard to locate patients around the globe and work with the investigative sites to create the best designs to maximise clinical programs and registries.
Orphan drug development is Ergomed’s core strength, and we are committed to helping those in need. Our expert team allows our clients to implement patient driven solutions in their clinical trials, and we believe that patients will define our future landscape, including the rise of both precision and preventative medicine.
Following are the key factors that set Ergomed and PSR’s joint expertise apart: